US Stock MarketDetailed Quotes

Immutep (IMMP)

Watchlist
  • 0.3733
  • +0.0482+14.83%
Close Sep 11 16:00 ET
  • 0.3502
  • -0.0231-6.19%
Post 20:02 ET
55.01MMarket Cap-0.97P/E (TTM)

About Immutep Company

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Company Profile

SymbolIMMP
Company NameImmutep
Listing DateApr 16, 2012
ISINUS45257L1089
Founded1987
CEOMr. Marc Voigt
MarketNASDAQ
Employees51
Securities TypeDR
ADS Ratio1 : 10
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer and Chief Financial Officer
  • 1.17M
  • Professor Dr. Frederic Triebel, M.D.
  • Executive Director and Chief Scientific Officer
  • 945.88K
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 680.39K
  • Christian Mueller
  • Chief Development Officer
  • 505.98K
  • Dr. Stephan Winckels, M.D.,PhD
  • Chief Medical Officer
  • --
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 76.48K
  • Dr. Russell J. Howard, PhD
  • Chairman of the Board
  • 352.00K
  • Lis Boyce
  • Independent Director
  • 100.85K
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On September 1, U.S. Eastern Time, the U.S. military launched a new round of strikes against Iran in response to recent attempts by the Isla Show More